Aarti Drugs Limited (IN:AARTIDRUGS)
:AARTIDRUGS
Want to see IN:AARTIDRUGS full AI Analyst Report?
AARTIDRUGS Stock Chart & Stats
₹404.80
-₹2.25(-0.50%)
At close: 4:00 PM EST
₹404.80
-₹2.25(-0.50%)
Day’s Range― - ―
52-Week Range₹318.60 - ₹574.95
Previous CloseN/A
Volume68.36K
Average Volume (3M)11.99K
Market Cap
₹33.46B
Enterprise Value₹40.52B
Total Cash (Recent Filing)₹245.40M
Total Debt (Recent Filing)₹5.73B
Price to Earnings (P/E)23.2
Beta0.98
Next Earnings
May 11, 2026Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)4.40
Shares Outstanding91,270,000
10 Day Avg. Volume14,342
30 Day Avg. Volume11,994
Financial Highlights & Ratios
PEG Ratio-16.53
Price to Book (P/B)2.30
Price to Sales (P/S)1.32
P/FCF Ratio46.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹480.00Price Target Upside18.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)24.7
Revenue Forecast (FY)₹29.50B
Bulls Say, Bears Say
Bulls Say
Diversified Product Portfolio (APIs, Intermediates, Specialty Chemicals)Aarti Drugs sells APIs, pharmaceutical intermediates and specialty chemicals to domestic and international customers. This product and market diversification supports durable revenue streams, reduces single-market risk and allows the company to capture higher-margin specialized products over time.
Manageable Leverage And Balanced Balance SheetThe firm's moderate debt-to-equity and overall balance sheet stability provide financial flexibility. Manageable leverage helps absorb cyclical demand, fund working capital or selective capex, and reduces refinancing risk, supporting operational resilience over the coming months.
Consistent Profitability And Adequate MarginsAdequate gross and net margins and a consistent return on equity indicate the business can generate sustainable profits from operations. Stable profitability in a specialty chemicals/APIs model supports reinvestment capacity and long-term viability despite cyclical pressures.
Bears Say
Recent Revenue Decline And Slowing Top-line GrowthA recent drop in revenue signals weaker demand or lost volumes/price pressure. Persistent top-line softness reduces operating leverage, limits margin recovery potential and constrains the company’s ability to expand or invest, increasing execution risk over the medium term.
Weak Free Cash Flow Generation TrendsDeclining free cash flow and volatile operating cash flow weaken self-funded growth capacity. Reduced FCF limits the ability to pay down debt, fund capex or return cash to shareholders, making the company more vulnerable to external financing stress during downturns.
Exposure To Input-cost And Pricing VolatilityMargins and volumes are sensitive to raw-material costs, customer demand and regulatory compliance. In APIs and specialty chemicals, input-cost swings or tighter quality rules can materially compress margins and disrupt supply contracts, creating sustained earnings unpredictability.
Aarti Drugs Limited News
AARTIDRUGS FAQ
What was Aarti Drugs Limited’s price range in the past 12 months?
Aarti Drugs Limited lowest stock price was ₹318.60 and its highest was ₹574.95 in the past 12 months.
What is Aarti Drugs Limited’s market cap?
Aarti Drugs Limited’s market cap is ₹33.46B.
When is Aarti Drugs Limited’s upcoming earnings report date?
Aarti Drugs Limited’s upcoming earnings report date is May 11, 2026 which is in 13 days.
How were Aarti Drugs Limited’s earnings last quarter?
Aarti Drugs Limited released its earnings results on Feb 03, 2026. The company reported ₹4.4 earnings per share for the quarter, missing the consensus estimate of ₹4.9 by -₹0.5.
Is Aarti Drugs Limited overvalued?
According to Wall Street analysts Aarti Drugs Limited’s price is currently Undervalued.
Does Aarti Drugs Limited pay dividends?
Aarti Drugs Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.24%. See more information on Aarti Drugs Limited dividends here
What is Aarti Drugs Limited’s EPS estimate?
Aarti Drugs Limited’s EPS estimate is 5.
How many shares outstanding does Aarti Drugs Limited have?
Aarti Drugs Limited has 91,270,000 shares outstanding.
What happened to Aarti Drugs Limited’s price movement after its last earnings report?
Aarti Drugs Limited reported an EPS of ₹4.4 in its last earnings report, missing expectations of ₹4.9. Following the earnings report the stock price went up 2.152%.
Which hedge fund is a major shareholder of Aarti Drugs Limited?
Currently, no hedge funds are holding shares in IN:AARTIDRUGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
AARTIDRUGS Stock 12 Month Forecast
Average Price Target
₹480.00
▲(18.58% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―